Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

PURPOSE: CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to malignant cells and maximize clinical activity. CC-486 300 mg daily, administered for 14 or 21 days of 28-day treatment cycles, is currently under investigation in two o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Babiker, Hani M., Milhem, Mohammed, Aisner, Joseph, Edenfield, William, Shepard, Dale, Savona, Michael, Iyer, Swaminathan, Abdelrahim, Maen, Beach, C. L., Skikne, Barry, Laille, Eric, Tsai, Kao-Tai, Ho, Thai
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Short Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7036073/
https://ncbi.nlm.nih.gov/pubmed/32036412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04037-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars